Cargando…

Appropriate vitamin D loading regimen for patients with advanced lung cancer

BACKGROUND: Most patients attending cancer clinics have hypovitaminosis D. Correcting or preventing this abnormal condition could mitigate the emotional and physical complications of their disease, but clinical trials of vitamin D therapy in this setting are hindered by the unavailability of safe, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffer, L. John, Robitaille, Line, Swinton, Nelda, Agulnik, Jason, Cohen, Victor, Small, David, Pepe, Carmela, Eintracht, Shaun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053167/
https://www.ncbi.nlm.nih.gov/pubmed/27716304
http://dx.doi.org/10.1186/s12937-016-0203-8
_version_ 1782458360570839040
author Hoffer, L. John
Robitaille, Line
Swinton, Nelda
Agulnik, Jason
Cohen, Victor
Small, David
Pepe, Carmela
Eintracht, Shaun
author_facet Hoffer, L. John
Robitaille, Line
Swinton, Nelda
Agulnik, Jason
Cohen, Victor
Small, David
Pepe, Carmela
Eintracht, Shaun
author_sort Hoffer, L. John
collection PubMed
description BACKGROUND: Most patients attending cancer clinics have hypovitaminosis D. Correcting or preventing this abnormal condition could mitigate the emotional and physical complications of their disease, but clinical trials of vitamin D therapy in this setting are hindered by the unavailability of safe, effective and practical loading dose regimens. METHODS: In this single arm open-label pharmacokinetic trial, outpatients with advanced lung cancer consumed 20,000 IU vitamin D daily with the largest meal of the day for 14 days followed by 10,000 IU per day for a further 7 days. Plasma concentrations of 25-hydroxyvitamin D [25(OH)D], parathyroid hormone, calcium, vitamin C and C-reactive protein were measured on protocol days 0, 14 and 21, and serum vitamin D binding protein (VDBP) concentrations on days 0 and 21. As a secondary objective, preliminary information was obtained regarding clinical effects of rapid vitamin D loading on mood and symptoms by administering appropriate questionnaires two times at baseline and after 14 and 21 days of vitamin D therapy. RESULTS: Of the 91 patients enrolled in the study, 85 % had hypovitaminosis D and 41 % had hypovitaminosis C. Plasma VDBP concentrations were in the normal range. The vitamin D load increased the average plasma 25(OH)D concentration to 116 ± 34 nmol/L (mean ± SD); the median concentration was 122 nmol/L (interquartile range 103–134); VDBP concentrations did not change. Final plasma 25(OH)D concentrations were subnormal (<75 nmol/L) for 13 % of the patients and sub-target (<120 nmol/L) for 44 % of them. In most cases, subnormal and sub-target 25(OH)D concentrations were attributable to obesity and/or a low baseline 25(OH)D concentration. Mood and symptom scores did not change significantly throughout the 3-week protocol. CONCLUSION: Hypovitaminosis D and C are very common in outpatients with advanced lung cancer. A vitamin D load of 20,000 IU per day for 14 days failed to achieve the target concentration in 44 % of the participants in this trial. These results suggest that a loading dose of 30,000 IU per day for 14 days would be safe and effective for patients who are obese or at risk of severe hypovitaminosis D. The preliminary nature of the study design, and the failure to achieve target 25(OH)D concentrations for a large proportion of the patients, do not allow any firm conclusion about the clinical effects of correcting hypovitaminosis D in this patient population. Nevertheless, no evidence was obtained that partial correction of hypovitaminosis D greatly improved mood, reduced distress or relieved cancer-related symptoms. This trial was registered at clinicaltrials.gov as NCT01631526.
format Online
Article
Text
id pubmed-5053167
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50531672016-10-18 Appropriate vitamin D loading regimen for patients with advanced lung cancer Hoffer, L. John Robitaille, Line Swinton, Nelda Agulnik, Jason Cohen, Victor Small, David Pepe, Carmela Eintracht, Shaun Nutr J Research BACKGROUND: Most patients attending cancer clinics have hypovitaminosis D. Correcting or preventing this abnormal condition could mitigate the emotional and physical complications of their disease, but clinical trials of vitamin D therapy in this setting are hindered by the unavailability of safe, effective and practical loading dose regimens. METHODS: In this single arm open-label pharmacokinetic trial, outpatients with advanced lung cancer consumed 20,000 IU vitamin D daily with the largest meal of the day for 14 days followed by 10,000 IU per day for a further 7 days. Plasma concentrations of 25-hydroxyvitamin D [25(OH)D], parathyroid hormone, calcium, vitamin C and C-reactive protein were measured on protocol days 0, 14 and 21, and serum vitamin D binding protein (VDBP) concentrations on days 0 and 21. As a secondary objective, preliminary information was obtained regarding clinical effects of rapid vitamin D loading on mood and symptoms by administering appropriate questionnaires two times at baseline and after 14 and 21 days of vitamin D therapy. RESULTS: Of the 91 patients enrolled in the study, 85 % had hypovitaminosis D and 41 % had hypovitaminosis C. Plasma VDBP concentrations were in the normal range. The vitamin D load increased the average plasma 25(OH)D concentration to 116 ± 34 nmol/L (mean ± SD); the median concentration was 122 nmol/L (interquartile range 103–134); VDBP concentrations did not change. Final plasma 25(OH)D concentrations were subnormal (<75 nmol/L) for 13 % of the patients and sub-target (<120 nmol/L) for 44 % of them. In most cases, subnormal and sub-target 25(OH)D concentrations were attributable to obesity and/or a low baseline 25(OH)D concentration. Mood and symptom scores did not change significantly throughout the 3-week protocol. CONCLUSION: Hypovitaminosis D and C are very common in outpatients with advanced lung cancer. A vitamin D load of 20,000 IU per day for 14 days failed to achieve the target concentration in 44 % of the participants in this trial. These results suggest that a loading dose of 30,000 IU per day for 14 days would be safe and effective for patients who are obese or at risk of severe hypovitaminosis D. The preliminary nature of the study design, and the failure to achieve target 25(OH)D concentrations for a large proportion of the patients, do not allow any firm conclusion about the clinical effects of correcting hypovitaminosis D in this patient population. Nevertheless, no evidence was obtained that partial correction of hypovitaminosis D greatly improved mood, reduced distress or relieved cancer-related symptoms. This trial was registered at clinicaltrials.gov as NCT01631526. BioMed Central 2016-10-06 /pmc/articles/PMC5053167/ /pubmed/27716304 http://dx.doi.org/10.1186/s12937-016-0203-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hoffer, L. John
Robitaille, Line
Swinton, Nelda
Agulnik, Jason
Cohen, Victor
Small, David
Pepe, Carmela
Eintracht, Shaun
Appropriate vitamin D loading regimen for patients with advanced lung cancer
title Appropriate vitamin D loading regimen for patients with advanced lung cancer
title_full Appropriate vitamin D loading regimen for patients with advanced lung cancer
title_fullStr Appropriate vitamin D loading regimen for patients with advanced lung cancer
title_full_unstemmed Appropriate vitamin D loading regimen for patients with advanced lung cancer
title_short Appropriate vitamin D loading regimen for patients with advanced lung cancer
title_sort appropriate vitamin d loading regimen for patients with advanced lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053167/
https://www.ncbi.nlm.nih.gov/pubmed/27716304
http://dx.doi.org/10.1186/s12937-016-0203-8
work_keys_str_mv AT hofferljohn appropriatevitamindloadingregimenforpatientswithadvancedlungcancer
AT robitailleline appropriatevitamindloadingregimenforpatientswithadvancedlungcancer
AT swintonnelda appropriatevitamindloadingregimenforpatientswithadvancedlungcancer
AT agulnikjason appropriatevitamindloadingregimenforpatientswithadvancedlungcancer
AT cohenvictor appropriatevitamindloadingregimenforpatientswithadvancedlungcancer
AT smalldavid appropriatevitamindloadingregimenforpatientswithadvancedlungcancer
AT pepecarmela appropriatevitamindloadingregimenforpatientswithadvancedlungcancer
AT eintrachtshaun appropriatevitamindloadingregimenforpatientswithadvancedlungcancer